{
    "clinical_study": {
        "@rank": "168215", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "patients will use placebo for 120 days"
            }, 
            {
                "arm_group_label": "Tribulus Terrestris", 
                "arm_group_type": "Experimental", 
                "description": "patients will use Tribulus terrestris (750 mg/day) during 120 days"
            }
        ], 
        "brief_summary": {
            "textblock": "Hypoactive Sexual Desire Disorder (HSDD) is the most prevalent female sexual dysfunction in\n      society and is strongly linked to the quality of life of women. The androgen hormones\n      decline over age in the premenopausal period, which occurs around 20 years. Tribulus\n      terrestris is a plant native to India, recommended in the treatment of infertility, low\n      libido and impotence. Its main active ingredient is the protodioscin, which has been\n      attributed to an increase in testosterone levels and improved sexual function. The aim of\n      this study is to evaluate the effects of Tribulus Terrestris in premenopausal women with\n      HSDD."
        }, 
        "brief_title": "Effects of Tribulus Terrestris in Women With Hypoactive Sexual Desire Disorder", 
        "condition": "Hypoactive Sexual Desire Disfunction", 
        "condition_browse": {
            "mesh_term": [
                "Sexual Dysfunctions, Psychological", 
                "Hypokinesia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  regular menstrual cycle\n\n          -  with no  use of hormonal contraception within the last 3 months\n\n          -  without any medication, drugs or alcohol.\n\n          -  Healthy patients without systemic or psychiatric disease\n\n        Exclusion Criteria:\n\n          -  Patients with amenorrhea and/or pregnant.\n\n               -  Patients who underwent bilateral oophorectomy.\n\n               -  Patient smoker (10 cigarettes per day).\n\n               -  Patients with blood pressure > 160/90 mm \u200b\u200bHg.\n\n               -  Patient with breast or endometrial carcinoma.\n\n               -  Patients with a history of myocardial infarction.\n\n               -  Patient with Diabetes.\n\n               -  Patient with vaginal bleeding from any source.\n\n               -  Patients with hepatic injury.\n\n               -  Patients with active thrombophlebitis or thromboembolic disorders recent\n\n               -  Patients with interpersonal relationship problems with your relationship or\n                  partner\n\n               -  Patients with sexual problems from your partner"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01971099", 
            "org_study_id": "TTM1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tribulus Terrestris", 
                "description": "patients will use 750mg/day of tribulus terrestris", 
                "intervention_name": "tribulus terrestris", 
                "intervention_type": "Drug", 
                "other_name": "tribulus"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "patients will take one pill a day (the same shape of the drug)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "sexual function", 
            "hypoactive", 
            "desire", 
            "androgens"
        ], 
        "lastchanged_date": "October 29, 2013", 
        "location": {
            "contact": {
                "email": "sjgeber@terra.com.br", 
                "last_name": "Selmo Geber, MD PhD", 
                "phone": "55 31 34099304"
            }, 
            "contact_backup": {
                "email": "fabienebcv@yahoo.com.br", 
                "last_name": "Fabiene Valle, MD", 
                "phone": "55 31 34099664"
            }, 
            "facility": {
                "address": {
                    "city": "Belo Horizonte", 
                    "country": "Brazil", 
                    "state": "Minas Gerais", 
                    "zip": "30130100"
                }, 
                "name": "Hospital das Clinicas - Universidade Federal de Minas Gerais"
            }, 
            "investigator": {
                "last_name": "Fabiene Vale, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "other_outcome": {
            "description": "blood test", 
            "measure": "serum levels of testosterone and sex hormone-binding globulin (SHBG)", 
            "safety_issue": "No", 
            "time_frame": "120 days"
        }, 
        "overall_contact": {
            "email": "sjgeber@terra.com.br", 
            "last_name": "Selmo Geber, MD PhD", 
            "phone": "55 31 34099304"
        }, 
        "overall_contact_backup": {
            "email": "fabienebcv@yahoo.com.br", 
            "last_name": "Fabiene Valle, MD", 
            "phone": "55 31 34099764"
        }, 
        "overall_official": {
            "affiliation": "Federal University of Minas Gerais", 
            "last_name": "Selmo Geber, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "we will use the \"Quotient Sexual - Version Feminine (QS-F) brazilian questionary to make the evaluation", 
            "measure": "Sexual Desire", 
            "safety_issue": "No", 
            "time_frame": "120 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01971099"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Federal University of Minas Gerais", 
            "investigator_full_name": "Selmo Geber", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "blood test", 
            "measure": "serum levels of prolactin and thyroid-stimulating hormone (TSH)", 
            "safety_issue": "No", 
            "time_frame": "120 days"
        }, 
        "source": "Federal University of Minas Gerais", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Federal University of Minas Gerais", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}